Entero Therapeutics, Inc.
ENTO
$1.91
$0.010.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.08M | -24.89M | -18.06M | -9.92M | -10.78M |
| Total Depreciation and Amortization | -33.00K | 2.30K | 14.60K | 56.20K | 62.20K |
| Total Amortization of Deferred Charges | 0.00 | 5.80K | 5.80K | 5.80K | 5.80K |
| Total Other Non-Cash Items | 11.03M | 16.20M | 6.29M | -4.25M | -4.10M |
| Change in Net Operating Assets | 3.19M | 2.39M | 2.53M | 1.62M | 833.70K |
| Cash from Operations | -2.89M | -6.29M | -9.22M | -12.49M | -13.97M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | 0.00 | 88.20K | 88.20K | 88.20K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -500.00K | -500.00K |
| Cash from Investing | 0.00 | 0.00 | 88.20K | -411.80K | -411.80K |
| Total Debt Issued | 700.00K | 731.80K | 31.80K | 31.80K | 31.80K |
| Total Debt Repaid | -177.60K | -418.60K | -644.60K | -644.60K | -620.50K |
| Issuance of Common Stock | 1.73M | 2.62M | 6.23M | 10.58M | 14.40M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.22M | 2.90M | 5.58M | 9.97M | 13.81M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -672.50K | -3.39M | -3.55M | -2.93M | -573.60K |